Severe hemolytic anemia and skin reaction in a patient treated with imatinib [4]

Annals of Oncology

Volumn 14, Issue 6, 2003, Pages 962-

  De Arriba, J J ^a   Nerin C ^a   Garcia E ^a   Gomez Aldaravi L ^a   Vila, B ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; DEXCHLORPHENIRAMINE; FENTANYL; IMATINIB; METOCLOPRAMIDE; OMEPRAZOLE; PREDNISONE;

ADRENAL TUMOR; ADULT; CASE REPORT; DERMATITIS; DRUG WITHDRAWAL; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOLYTIC ANEMIA; HEPATOMEGALY; HUMAN; LETTER; LIVER METASTASIS; PRIORITY JOURNAL; PRURITUS; SKIN MANIFESTATION; SPLEEN TUMOR; STOMACH TUMOR; ULTRASOUND;

ADRENAL GLAND NEOPLASMS; ANEMIA, HEMOLYTIC; ANTINEOPLASTIC AGENTS; EXANTHEMA; FEMALE; HUMANS; LIVER NEOPLASMS; MIDDLE AGED; PIPERAZINES; PYRIMIDINES; RISK FACTORS; SPLENIC NEOPLASMS; STOMACH NEOPLASMS;

EID: 0038349650     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg245     Document Type: Letter

References (4)

1. Savage DG, Antman KH. Imatinib mesylate. A new oral targeted therapy. N Engl J Med 2002; 346: 686-693.
2. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imanitib therapy. Blood 2002; 100: 3434-3435.
3. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med 2001; 345: 618-619.
4. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.